Actively Recruiting
Randomized Placebo-Controlled Trial Evaluating Doses of HRS-9821 Inhalation Suspension in Adults with Moderate to Severe COPD
Led by Guangdong Hengrui Pharmaceutical Co., Ltd · Updated on 2026-08-18
90
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying HRS-9821 Inhalation Suspension to evaluate its safety and effectiveness for adults with moderate to severe Chronic Obstructive Pulmonary Disease COPD. This study also aims to find the appropriate dosage of HRS-9821 for these patients. The trial is a randomized, double-blind, placebo-controlled Phase II clinical trial sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Participants are assigned to one of four groups receiving either one of two doses of HRS-9821 or a matching placebo inhalation suspension. Treatments are given over a 28-day period. The study compares lung function and respiratory symptoms between groups, including measurements like forced expiratory volume and forced vital capacity. The trial uses inhalation suspensions administered regularly to assess effects on COPD symptoms and lung capacity. During the 28 days of treatment, participants will have lung function tests, questionnaires on respiratory health, and monitoring of medication use. Researchers will measure changes in peak lung function, symptom scores, and use of rescue medication. Safety and efficacy are carefully monitored throughout. The total participation time aligns with the 28-day treatment and includes follow-up for lung function and symptom evaluation.
CONDITIONS
Brief Title
A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Research Team
S
Si Chen, M.M
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here